Literature DB >> 17407106

The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers.

Michael E Kupferman1, William H Morrison, Alfredo A Santillan, Dianna Roberts, Eduardo M Diaz, Adam S Garden, Randal Weber.   

Abstract

BACKGROUND: The role of interstitial brachytherapy (IBT) in the salvage surgical management of regional lymphatic metastases for head and neck cancer has not been defined to date. To further explore its therapeutic benefit in the management of head and neck squamous cell carcinoma, the authors reviewed their experience utilizing IBT at the M. D. Anderson Cancer Center.
METHODS: A retrospective chart review of all patients who were received IBT for cervical recurrences of head and neck cancer was undertaken. Twenty-two patients were identified; all patients underwent neck dissection and intraoperative placement of afterloading catheters as part of the salvage treatment. Soft tissue reconstruction was performed when necessary. The duration and dosage of salvage brachytherapy was reviewed, and the overall disease-free survival rates were determined.
RESULTS: All patients had been treated with external beam radiation therapy prior to recurrence, with an average dose of 65 grays (Gy), and 46% of patients had undergone prior neck dissection. The median time to regional recurrence after definitive treatment was 30 months. Soft tissue coverage of the surgical bed with a muscle flap, most commonly a pectoralis major flap, was performed in 19 of 22 patients. The median IBT dose was 60 Gy over a total duration of 4 days. Postoperative complications were few, and there were no perioperative deaths. Recurrences in the reirradiated necks occurred in 27% of patients.
CONCLUSIONS: Regional recurrences are common after multimodality treatment for head and neck cancer and are challenging to manage. Although its role has not been defined clearly, salvage neck dissection with IBT is beneficial in the management of recurrent lymphatic metastases of upper aerodigestive tract carcinomas. (c) 2007 American Cancer Society

Entities:  

Mesh:

Year:  2007        PMID: 17407106     DOI: 10.1002/cncr.22648

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Intensity modulated perioperative HDR brachytherapy for recurrent and/or advanced head and neck metastases.

Authors:  Ingo U Teudt; György Kovàcs; Matthias Ritter; Corinna Melchert; Tamer Soror; Barbara Wollenberg; Jens E Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

Review 2.  Head and neck cancer: an evolving treatment paradigm.

Authors:  David M Cognetti; Randal S Weber; Stephen Y Lai
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: Long-term results.

Authors:  Vratislav Strnad; Michael Lotter; Stephan Kreppner; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2015-01-10       Impact factor: 3.621

4.  Bronchoscopic interventions combined with percutaneous modalities for the treatment of thyroid cancers with airway invasion.

Authors:  Hongwu Wang; Meimei Tao; Nan Zhang; Lingfei Luo; Dongmei Li; Hang Zou; Yunzhi Zhou; Sujuan Liang
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-19       Impact factor: 2.503

Review 5.  Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.

Authors:  György Kovács
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

6.  The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers.

Authors:  Nayel Khan; Mark Clemens; Jun Liu; Adam S Garden; Anne Lawyer; Randal Weber; G Brandon Gunn; William H Morrison; Michael E Kupferman
Journal:  Cancers Head Neck       Date:  2019-07-22

Review 7.  A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.

Authors:  Julianna Rodin; Voichita Bar-Ad; David Cognetti; Joseph Curry; Jennifer Johnson; Chad Zender; Laura Doyle; David Kutler; Benjamin Leiby; William Keane; Adam Luginbuhl
Journal:  J Contemp Brachytherapy       Date:  2018-10-31

8.  Reirradiation of recurrent head and neck cancer using high-dose-rate brachytherapy.

Authors:  V Rudzianskas; A Inciura; E Juozaityte; M Rudzianskiene; R Kubilius; S Vaitkus; M Kaseta; D Adliene
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-10       Impact factor: 2.124

9.  Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes.

Authors:  Anthony Pham; Shruthi Arora; A Gabriella Wernicke; David I Kutler; Marc Cohen; William Kuhel; Samuel Trichter; Dattatreyudu Nori; Silvia C Formenti; Bhupesh Parashar
Journal:  J Contemp Brachytherapy       Date:  2015-12-30

10.  Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.

Authors:  M Ritter; I U Teudt; J E Meyer; U Schröder; G Kovács; B Wollenberg
Journal:  Radiat Oncol       Date:  2016-01-20       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.